tbuckley/cabot-search huggingface dataset:
Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.
Authors: Daniel Primo, Javier De la Serna, Joaquin Martinez, Marcos González, Javier Lopez, Abelardo Bárez, Macarena Ortiz, Javier Loscertales, Julian Vidán, Alicia Rodriguez, Marta Polo, Sandra Irhaeta, Jose Maria Alonso, Jose Antonio Queizan, Jose Angel Hernandez Rivas, María Jesus Peñarrubia, Julian Gorrochategui, Ana Belen Espinosa, Elena Arroyo, Melanie Oates, Andrew R Pettit, Joan Ballesteros, Pilar Hernandez
Journal: Blood (2014)
Toward understanding patient experience in idiopathic pulmonary fibrosis
Authors: Sonye K. Danoff
Journal: European Respiratory Journal (2017)

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease which typically presents in the 6th or 7th decade of life with dyspnoea on exertion, cough and fatigue [1]. Based on a recent systematic review [2], global IPF incidence is 3–9 cases per 100 000 per year in Europe and North America with increasing incidence over time. A similar incidence, 9 cases per 100 000, was reported in Canada using a narrow definition of IPF [3]. The age-adjusted mortality rate for IPF ranges from 2 to 10 per 100 000, resulting in an estimated 30 000–60 000 deaths in Europe in 2014 [4]. Despite the large number of individuals impacted by this nominally rare disease, there has been only one intervention proven to increase life expectancy in IPF and that is lung transplantation [5]. The small number of lung transplants available, and the common comorbidities of aging which accompany IPF, make this an inadequate intervention for the majority of patients. Unfortunately, over the past 40 years, multiple clinical trials in IPF have failed to achieve pre-specified primary outcomes. Validation of patient-reported outcomes in IPF is essential in incorporating patient voice in IPF clinical trials <http://ow.ly/hyNM306jeGR>
Multiparameter Flow Cytometry (MFC) for Identification of the Waldenström's Clone in IgM MGUS and Waldenstrom's Macroglobulinemia (WM): New Criteria for Differential Diagnosis and Risk Stratification
Authors: Bruno Paiva, Maria-Carmen Montes, Ramón García-Sanz, Jennifer Alonso, Natalia de las Heras, Fernando Escalante, Alfonso Garcia de Coca, Josefina Galende, Jose Hernández, Alejandro Martín, Emilia Pardal, Abelardo Bárez, Jose M Alonso, Alberto Orfao, Enrique M Ocio, María-Belén Vidriales, Jesus F. San Miguel
Journal: Blood (2012)
Involvement of Lipogenic Pathway In 5-Azacytidine-Induced Cytotoxicity In Waldenstrom's Macroglobulinemia
Authors: Lian Xu, Christopher Patterson, Jenny Sun, Guang Yang, Yangsheng Zhou, Zachary Hunter, Bryan Ciccarelli, Robert Manning, Xia Liu, Yang Cao, Hsiuyi Tseng, Leukothea Ioakimidis, Christina Hanzis, Steven P. Treon
Journal: Blood (2010)
The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.
Authors: Michelle Fanale, Nancy L Bartlett, Andres Forero-Torres, Joseph Rosenblatt, Sandra J Horning, Anna R Franklin, Carmel M Lynch, Eric L Sievers, Dana A Kennedy
Journal: Blood (2009)
SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development
Authors: Chunling Luo, Yuanming Cheng, Yuguo Liu, Linlin Chen, Lina Liu, Ning Wei, Zhiqin Xie, Wenwu Wu, Ying Feng
Journal: Cancer Research (2017)

Abstract Aberrant RNA splicing is recognized to contribute to cancer pathogenesis, but the underlying mechanisms remain mainly obscure. Here, we report that the splicing factor SRSF2 is upregulated frequently in human hepatocellular carcinoma (HCC), where this event is associated with poor prognosis in patients. RNA-seq and other molecular analyses were used to identify SRSF2-regulated alternative splicing events. SRSF2 binding within an alternative exon was associated with its inclusion in the RNA, whereas SRSF2 binding in a flanking constitutive exon was associated with exclusion of the alternative exon. Notably, cancer-associated splice variants upregulated by SRSF2 in clinical specimens of HCC were found to be crucial for pathogenesis and progression in hepatoma cells, where SRSF2 expression increased cell proliferation and tumorigenic potential by controlling expression of these variants. Our findings identify SRSF2 as a key regulator of RNA splicing dysregulation in cancer, with possible clinical implications as a candidate prognostic factor in patients with HCC. Cancer Res; 77(5); 1168–78. ©2017 AACR.
Mg2+ Is Required for Optimal Folding of the γ-Carboxyglutamic Acid (Gla) Domains of Vitamin K-Dependent Clotting Factors At Physiological Ca2+
Authors: Kanagasabai Vadivel, Sayeh Agah, Amanda S. Messer, Duilio Cascio, Madhu S Bajaj, Sriram Krishnaswamy, Charles T Esmon, Kaillathe Padmanabhan, S. Paul Bajaj
Journal: Blood (2011)
Evidence for Cooperation of Receptor Tyrosine Kinases and Activating NOTCH Mutations to Hyperactivate mTOR in T-Cell Leukemia: A Rationale Basis for Targeted Therapy
Authors: Adrian Schwarzer, Johann Meyer, Martijn Brugman, Axel Schambach, Martin Stanulla, Martin Schrappe, Doris Steinemann, Brigitte Schlegelberger, Christopher Baum, Zhixiong Li
Journal: Blood (2011)
Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)
Authors: Ferdinando Frigeri, Raffaele Di Francia, Luigi Petraccone, Concetta Giancola, Annunziata Cummaro, Paolo Danise, Stefania Crisci, Giancarla Iaccarino, Rosaria De Filippi, Emanuela Morelli, Gaetana Capobianco, Francesco Volzone, Alfonso Maria D'Arco, Antonio Pinto
Journal: Blood (2011)
Safety of Peripheral Hematopoietic Stem Cell Mobilization with Lenograstim in Allogeneic Healthy Donors ≥ 50 Years Old: A Single-Centre Experience
Authors: Massimo Martino, Antonella Dattola, Roberta Fedele, Antonella Pontari, Tiziana Moscato, Maria Cuzzola, Tiziana Martinello
Journal: Blood (2014)
Pandemic H1N1 influenza in Brazil: Analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI)
Authors: W K Oliveira, E H Carmo*, G O Penna, R S Kuchenbecker, H B Santos, W N Araujo, R Malaguti, B B Duncan, M I Schmidt, None on behalf of the Surveillance Team
Journal: Eurosurveillance (2009)

Recently, the brunt of the current influenza pandemic has been felt in the southern hemisphere. We report an analysis of the first 34,506 cases of influenza-like illness with severe acute respiratory infection (SARI) notified in Brazil during the epidemiological weeks 16 to 33. The 5,747 confirmed cases of pandemic H1N1 influenza showed two incidence peaks across the age span: one in children up to the age of five years (3.8/100,000) and one in individuals aged 20 to 29 years (4.6/100,000). People over the age of 60 had the lowest incidence (1.1/100,000 inhabitants). The epidemic peaked rapidly. Ninety-four percent of cases were concentrated in two of Brazil's five geographic regions – the south and southeast, regions that have a more temperate climate and thus colder winters. Case-fatality of pandemic influenza presenting with SARI was 11.2% (95% confidence interval (CI): 10.4%-12.1%). People with a reported comorbidity had approximately twice the risk of those without (relative risk=1.89; 95%CI: 1.64-2.18).
Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.
Authors: Don Benson, Craig C. Hofmeister, Swaminathan Padmanabhan, Rafat Abonour, Attaya Suvannasankha, Alain Mita, Patrick Squiban, Megan K Smith, Courtney E Bakan, Marc Marzetto, Pascale Andre, Jerome Tollier, Michael A. Caligiuri, Sherif Farag
Journal: Blood (2009)
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
Authors: Constantinos Petrovas, Sara Ferrando-Martinez, Michael Y. Gerner, Joseph P. Casazza, Amarendra Pegu, Claire Deleage, Arik Cooper, Jason Hataye, Sarah Andrews, David Ambrozak, Perla M. Del Río Estrada, Eli Boritz, Robert Paris, Eirini Moysi, Kristin L. Boswell, Ezequiel Ruiz-Mateos, Ilias Vagios, Manuel Leal, Yuria Ablanedo-Terrazas, Amaranta Rivero, Luz Alicia Gonzalez-Hernandez, Adrian B. McDermott, Susan Moir, Gustavo Reyes-Terán, Fernando Docobo, Giuseppe Pantaleo, Daniel C. Douek, Michael R. Betts, Jacob D. Estes, Ronald N. Germain, John R. Mascola, Richard A. Koup
Journal: Science Translational Medicine (2017)

LN inflammation in chronic HIV is associated with accumulation of follicular CD8 T cells that could be redirected to kill infected cells.
Establishment of a Retroviral Mouse Model for inv(16)-Mediated Acute Myeloid Leukemia Suggests That the p14ARF Tumor Suppressor Is a Transcriptional Target for Repression by the inv(16) Fusion Protein.
Authors: Isabel Moreno, Ling Pan, Jennifer Keates, Hyung Kim, Christopher Klug, Scott Hiebert
Journal: Blood (2004)
Immunohistochemical Expression of Vascular Endothelial Growth Factor Correlates with Microvessel Density in Ph− Chronic Myeloproliferative Disorders.
Authors: Claudia Vener, Umberto Gianelli, Paola Rafaniello Raviele, Federica Savi, Francesco Somalvico, Rossella Calori, Paolo Bucciarelli, Alessandra Iurlo, Franca Radaelli, Silvano Bosari, Giorgio Lambertenghi Deliliers
Journal: Blood (2006)
Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)
Authors: Sundar Jagannath, Ravi Vij, A. Keith Stewart, George Somlo, Andrzej Jakubowiak, Tony Reiman, Suzanne Trudel, Jessica Taylor, Diana Fuhrman, Scott Cruickshank, Richard Schwartz, Lori Kunkel, David Siegel
Journal: Blood (2008)
A landscape of circular RNA expression in the human heart
Authors: Wilson L.W. Tan, Benson T.S. Lim, Chukwuemeka G.O. Anene-Nzelu, Matthew Ackers-Johnson, Albert Dashi, Kelvin See, Zenia Tiang, Dominic Paul Lee, Wee Woon Chua, Tuan D.A. Luu, Peter Y.Q. Li, Arthur Mark Richards, Roger S.Y. Foo
Journal: Cardiovascular Research (2016)

Circular RNA (circRNA) is a newly validated class of single-stranded RNA, ubiquitously expressed in mammalian tissues and possessing key functions including acting as microRNA sponges and as transcriptional regulators by binding to RNA-binding proteins. While independent studies confirm the expression of circRNA in various tissue types, genome-wide circRNA expression in the heart has yet to be described in detail.We performed deep RNA-sequencing on ribosomal-depleted RNA isolated from 12 human hearts, 25 mouse hearts and across a 28-day differentiation time-course of human embryonic stem cell-derived cardiomyocytes. Using purpose-designed bioinformatics tools, we uncovered a total of 15 318 and 3017 cardiac circRNA within human and mouse, respectively. Their abundance generally correlates with the abundance of their cognate linear RNA, but selected circRNAs exist at disproportionately higher abundance. Top highly expressed circRNA corresponded to key cardiac genes including Titin (TTN), RYR2, and DMD. The most abundant cardiac-expressed circRNA is a cytoplasmic localized single-exon circSLC8A1-1. The longest human transcript TTN alone generates up to 415 different exonic circRNA isoforms, the majority (83%) of which originates from the I-band domain. Finally, we confirmed the expression of selected cardiac circRNA by RT-PCR, Sanger sequencing and single molecule RNA-fluorescence in situ hybridization.Our data provide a detailed circRNA expression landscape in hearts. There is a high-abundance of specific cardiac-expressed circRNA. These findings open up a new avenue for future investigation into this emerging class of RNA.
Longitudinal Analysis of Body Mass and Composition in Survivors of Pediatric Hematological Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Hiroto Inaba, Jie Yang, Sue Kaste, Christine Hartford, Megan S Motosue, Ashok Srinivasan, Brandon M. Triplett, David R Shook, Ching-Hon Pui, Wing Leung
Journal: Blood (2011)
Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents
Authors: Charles L. Bennett, Sony Jacob, Peter Georgantopoulos, Judy Nichols, Iain C Macdougall
Journal: Blood (2014)
Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL)
Authors: Jennifer R Brown, Michael S Lawrence, Megan Hanna, Bethany Tesar, Petar Stojanov, Alexander R. Vartanov, Stacey M Fernandes, Carrie Sougnez, Laura MacConaill, Nathalie Pochet, Aviv Regev, Lillian Werner, Stacey Gabriel, Eric S Lander, Donna Neuberg, Arnold S. Freedman, Gad Getz, Catherine J Wu
Journal: Blood (2011)
Reversal of Behavioral Deficits and Synaptic Dysfunction in Mice Overexpressing Neuregulin 1
Authors: Dong-Min Yin, Yong-Jun Chen, Yi-Sheng Lu, Jonathan C. Bean, Anupama Sathyamurthy, Chengyong Shen, Xihui Liu, Thiri W. Lin, Clifford A. Smith, Wen-Cheng Xiong, Lin Mei
Journal: Neuron (2013)
ATPS-79NOVEL MITOCHONDRIAL BASED CHEMOTHERAPY USING GLIOMA SPECIFIC MITOCHONDRIAL TARGETED DRUGS
Authors: David Baskin, Martyn Sharpe
Journal: Neuro-Oncology (2015)

We demonstrate that monoamine oxidase B (MAO-B) levels in glioma are far higher than in control brain, and that levels of MAO-B correlate with tumor grade. Monoamine oxidases are able to oxidize a wide range of N-methyl-1,2,3,6-tetrahydropyridine substrates into their respective N-methyl-pyridinium cations (P + -). We have designed a range of methyl-tetrahydropyridine (MP-) compounds that undergo MAO-B specific oxidation from the neutral pro-Drug/Dye species into mitochondrial targeting lipophilic compounds. Coupling methyl-tetrahydropyridine to the neutral fluorophore Bodipy, via a linker, produces MP-Bodipy. In vitro we show that this compound is rapidly converted into the mitochondria targeting cation P + -Bodipy by MAO-B. The conversion of MP-Bodipy into P + -Bodipy is abolished by preincubation with the MAO-B specific inhibitor, Selegiline, and mitochondrial accumulation of P + -Bodipy can be reversed by using an uncoupling agent. MP-Bodipy is a highly specific probe in glioma xenografts in flank and in intracranial tumor models. This targeting of MAO-B overexpression should facilitate fluorescence-guided surgery allowing neurosurgeons to identify gliomal infiltration boundaries during tumor resection. Using a nitrogen mustard moiety (MUS) in place of the dye gives rise to a MAO-B specific MP-MUS/P + -MUS (pro-Drug/Drug) pair; a gliomal specific chemotherapeutic that targets glioma mitochondria via an attack on mitochondrial DNA. MP-MUS is highly effective in selectively damaging gliomal mitochondria, and leads to an alteration of cancer cell phenotype in the few cells that survive in vitro and in vivo. MP-MUS effectively treats primary gliomal xenografts in both flank and intracranial tumor models. In an intracranial xenograft model, over 50% of all animals are completely tumor free with only three treatments of MP-MUS, without causing any significant toxicity in tissues. The others all have minimal tumor left. A wide range of mitochondrial toxins can be coupled to the MAO-B specific MP-/P + - pair allowing us to optimize our drugs for an individual glioma.
Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML.
Authors: Derek L. Stirewalt, Todd A. Alonzo, Era L. Pogosova-Agadjanyan, Robert B. Gerbing, Janet Franklin, Hana Lee, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2012)
State-Level Lifetime Medical and Work-Loss Costs of Fatal Injuries — United States, 2014
Authors: Feijun Luo, Curtis Florence
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Injury-associated deaths have substantial economic consequences in the United States. The total estimated lifetime medical and work-loss costs associated with fatal injuries in 2013 were $214 billion (1). In 2014, unintentional injury, suicide, and homicide (the fourth, tenth, and seventeenth leading causes of death, respectively) accounted for 194,635 deaths in the United States (2). In 2014, a total of 199,756 fatal injuries occurred in the United States, and the associated lifetime medical and work-loss costs were $227 billion (3). This report examines the state-level economic burdens of fatal injuries by extending a previous national-level study (1). Numbers and rates of fatal injuries, lifetime costs, and lifetime costs per capita were calculated for each of the 50 states and the District of Columbia (DC) and for four injury intent categories (all intents, unintentional, suicide, and homicide). During 2014, injury mortality rates and economic burdens varied widely among the states and DC. Among fatal injuries of all intents, the mortality rate and lifetime costs per capita ranged from 101.9 per 100,000 and $1,233, respectively (New Mexico) to 40.2 per 100,000 and $491 (New York). States can engage more effectively and efficiently in injury prevention if they are aware of the economic burden of injuries, identify areas for immediate improvement, and devote necessary resources to those areas.
Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia
Authors: Farhad Ravandi, Jorgensen L Jeffrey, Elias J Jabbour, Gautam Borthakur, Tapan Kadia, Stefan Faderl, Sherry Pierce, Mark Brandt, Sa A. Wang, Sergej Konoplev, Naval Daver, Naveen Pemmaraju, Guillermo Garcia-Manero, Michael Andreeff, Marina Konopleva, Jorge E. Cortes, Hagop M. Kantarjian
Journal: Blood (2015)
Dominance of Non-CLL Phenotype of Monoclonal B-Cell Lymphocytosis (MBL) in the Middle East and An Overall MBL Prevalence Comparable to Western Countries
Authors: Maher Albitar, Faisal Rawas, Randa Nounou, Nasir Bakshi, Fahed Almhareb, Hazzaa Al Zahrani, Said Mohamed, Walid Rasheed, Salem Khalil, Fahad Alsharif, Naeem A. Chaudhri, Hassan El-Solh, Mahmoud Aljurf
Journal: Blood (2011)
Clinical experience of percutaneous transluminal coronary angioplasty.
Authors: Youichi Shimizu, Toshihide Tanaka, Yasuo Takayama, Yukiyoshi Ito, Mitsuki Abe, Mitsukazu Matsuda, Takayuki Sakakibara, Yoshio Obunai
Journal: Circulation (1984)

PTCA (percutaneous transluminal coronary angioplasty) was performed on 44 patients with angina pectoris during the 18-month period from April 10, 1981 to September 30, 1982. It was successful in 36 of the 44 patients (82%), resulting in a subsidence of the symptoms and a considerable increase in exercise tolerance. Successful dilatations were achieved in 30 of 35 left anterior descending arteries (86%) and 7 of 11 right coronary arteries (64%). Five patients had complications: myocardial infarction in 2, unstable angina pectoris in 1, and dissection of the coronary artery in 2. One of these patients underwent an urgent A-C bypass operation. The patients were followed up for 0.5 to 18 months (average: 7.4 +/- 0.9 months). Stenosis recurred in 6 patients (16.7%), but repeat PTCA disclosed successful dilatations of stenotic lesions in 3 patients. No deaths occurred throughout the study period including the follow-up period. Our experience suggests that PTCA is of use in the treatment of certain groups of angina pectoris patients if case selection is appropriate.
Management strategies for atrial fibrillation
Authors: Peysh A Patel, Noman Ali, Andrew Hogarth, Muzahir H Tayebjee
Journal: Journal of the Royal Society of Medicine (2017)

Atrial fibrillation is the most prevalent cardiac arrhythmia, affecting 10% of those aged over 80 years. Despite multiple treatment options, it remains an independent prognostic marker of mortality due to its association with clinical sequelae, particularly cerebrovascular events. Management can be broadly divided into treatment of the arrhythmia, via rhythm or rate control, and stroke thromboprophylaxis via anticoagulation. Traditional options for pharmacotherapy include negatively chronotropic drugs such as β-blockers, and/or arrhythmia-modifying drugs such as amiodarone. More recently, catheter ablation has emerged as a suitable alternative for selected patients. Additionally, there has been extensive research to assess the role of novel oral anticoagulants as alternatives to warfarin therapy. There is mounting evidence to suggest that they provide comparable efficacy, while being associated with lower bleeding complications. While these findings are promising, recent controversies have arisen with the use of novel oral anticoagulants. Further research is warranted to fully elucidate mechanisms and establish antidotes so that treatment options can be appropriately directed.
Correlative Cellular Analyses in a Phase I Trial (Safety and Efficacy of Autologous Intracoronary Stem Cell Injections in Total Coronary Artery Occlusions (SEACOAST)) of Autologous Bone Marrow-Derived CD133 Cells.
Authors: N.J. Greco, V.J. Pompili, H.M. Lazarus, D. Adler, T. Lasser, R. Fox, L. Solchaga, L. Rinkes, L. Mazzurco, L. Hickel, R. Nair, H. Meyerson, M. Finney, M. Kozik, L.R. Fanning, M. Joseph, S. Bhakta, J. Goldberg, Mary J. Laughlin
Journal: Blood (2006)
Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.
Authors: Gareth J. Morgan, Stephen Schey, Ping Wu, M. Srikanth, Karen J. Phekoo, Matthew W. Jenner, Sharon Dines, Radovan Saso, Faith E. Davies
Journal: Blood (2006)
Frequency of Genetic Deletions of the Glutathione-S Transferase (Gst) Gene in Mexican Patients with De Novo Acute Leukemia: A Preliminary Report from the “Instituto Tecnologico De Monterrey-Hematology Research Group”.
Authors: Jose R. Borbolla Escoboza, Marcos E. Garza-Madrid, Martha Alvarado, Enrique Baez, Manuel A. Lopez-Hernández, Jose E. DeDiego, Severiano Baltazar, Maria I. Leon-Castanon, Julio C. Rojas-Martinez, Cecilia Ramirez-Assad, Elvira Trueba, Gerardo Villarreal, Luis M. Villela, Jorge Cruz-Rico, Monica Tejeda, Jorge Duque, Mauricio C. Gonzalez-Avante, Teresa Pompa, Irene Anaya, Leonel Ochoa, Guadalupe Gonzalez, Maria de la Luz Mendizabal, Rosa M. Jimenez, Roberto Hernandez, Dolores Mejia, Eduardo Romero, Carlos Gil-Rondero, Jorge L. Juarez, Rosa E. De Leon, Yara E. Tovar, Jason A. Penniecook
Journal: Blood (2004)
Examining the Racial Disparities In Presentation and Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Pareen J Shenoy, Uma Borate, Kevin Bumpers, Tanyanika Douglas-Holland, Nassoma King, Mary Jo Lechowicz, David L Jaye, Will Donnellan, Angelina The, Vishnu Reddy, James M. Foran, Christopher R Flowers
Journal: Blood (2010)
Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome.
Authors: Vaishalee P. Kenkre, Sarah Horowitz, Sonali M. Smith, Andrew Artz, Kenneth S. Cohen, Lucy A Godley, Justin Kline, Wendy Stock, Koen van Besien
Journal: Blood (2009)
NF-kB as a Regulator of FA/BRCA Gene Expression in Multiple Myeloma.
Authors: Vasco A. Oliveira, Linda Mathews, Danielle Yarde, Xingyu Wang, David Boulware, Lori A. Hazlehurst, Dung-Tsa Chen, Amer Beg, William S. Dalton
Journal: Blood (2007)